CEO Blog: Timelines and Strategies

Posted on June 11th, 2018 by Blog Author

With NOX66 running in 3 separate clinical programs, there is considerable scope for priorities, commercial strategies, timelines etc to become blurred in shareholders’ minds. Hopefully this will make it clearer. …………………………………………………………………… In terms of priorities: The DARRT program in prostate cancer is #1. We regard this as our primary path to market approval and a […]

Read More